GM1 Intravenous AAV9 Gene Therapy Clinical Trial to Begin in the First Half of 2019

Cure GM1 Foundation contributed $422K to the preclinical program towards the development of the IV AAV9 gene therapy developed at UMass and Auburn University.

The Cure GM1 Foundation contributed significant funding to the preclinical work for this program.  Substantial funding was also provided by the National Institute of Health (NIH),  University of Massachusetts (UMass), Auburn University, and privately.

A biotech company Axovant will now carry the program forward through clinical trials and beyond.

Read the Press Release Here.

We look forward to a future with multiple clinical trials for GM1.

Please follow the web page and or our Facebook page for more news about this and other research being carried forward.

We will provide updates on inclusion criteria and the official start as the information becomes available.